Hematology

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Whether these findings will translate into a change in treatment guidelines remains to be seen.

Ropeginterferon alfa-2b-njft is expected to be available immediately.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists anticipate decline.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

Lymphomas arise from immune system cells and can create an environment less hospitable to CAR T-cell expansion, explained Kerry Rogers, MD.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

The study authors indicated that future investigations could further facilitate clinical decision-making regarding these regimens’ effectiveness.

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered.

Institutions need to think more creatively about how they identify and elevate talent, explains Bhavana Bhatnagar, DO.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

Drugs that form the backbone of CLL therapy are also used across lymphoma subtypes, explains Adam S. Kittai, MD.

Swarup Kumar, MD, of UConn Health, says iberdomide plus dara-dex fills a niche for relapsed disease in patients who lack access to CAR T or bispecifics.

Previous research shows that in newly diagnosed AML, CR and composite remission rates were higher for shortened regimens of venetoclax.

Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

This meta-analysis encompassed 18 studies published through December 31, 2025.

She frames the IberDd approval as more than the addition of 1 more regimen to a crowded relapsed/refractory myeloma armamentarium.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.

The disparity in outcomes between pediatric and young adult patients with ALL is multifactorial, explained Emily K. Curran, MD.

The BTK inhibitor also showed fewer severe adverse events and better patient-reported quality of life than chemoimmunotherapy.

Prior to receiving CAR T-cell therapy, patients undergo lymphodepletion chemotherapy, explained Kerry Rogers, MD, The James.